Previous 10 | Next 10 |
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 14, 2021 – USA News Group – Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq doing ev...
Gainers: Grove (NASDAQ:GRVI) +63%, NRx Pharmaceuticals (NASDAQ:NRXP) +34%, DarioHealth (NASDAQ:DRIO) +22%, Connect Biopharma (NASDAQ:CNTB) +21%, Annovis Bio (NYSE:ANVS) +15%. Losers: Jasper Therapeutics (NASDAQ:JSPR) -20%, PLx Pharma (NASDAQ:P...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NRX Pharmaceuticals (NASDAQ: NRXP ) stock is surging higher on Thursday thanks to recent results from a clinical trial of its Covid-19 treatment. Source: Shutterstock.com According to the results, 81% of pati...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bank stocks are on the move Thursday following the release of earnings reports from various companies. Source: Syda Productions / Shutterstock.com We’re diving into those earnings reports below to see what ha...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the previous meme stocks that went absolutely parabolic this year, Orphazyme (NASDAQ: ORPH ) has been on one heck of a crazy ride. Shares of this biopharma company surged in biblical parabolic fashion on June 1...
The following slide deck was published by Orphazyme A/S in conjunction with their 2021 Q2 earnings call. For further details see: Orphazyme A/S 2021 Q2 - Results - Earnings Call Presentation
Orphazyme A/S (ORPH) Q2 2021 Earnings Conference Call August 31, 2021 8:00 A.M. ET Company Participants Amy Conrad - Investor Relations Christophe Bourdon - Chief Executive Officer Anders Vadsholt - Chief Financial Officer Conference Call Participants Disclaimer*: This transcript is designed ...
Triple-S Management (NYSE:GTS) +44% to be acquired by GuideWell in an all-cash deal worth $900 million Bio-Path (NASDAQ:BPTH) +32% on FDA clearance of BP1002 application in acute myeloid leukemia Cara Therapeutics (NASDAQ:CARA) +21% and Vifor Pharma announce U.S. FDA ...
12-Month Study of Arimoclomol Showed a Clinically Meaningful Treatment Effect, Corresponding to a Reduction in Disease Progression Highlights Arimoclomol is Under Regulatory Review in Europe, With a Decision Expected in Q4 2021 Notes Orphazyme Stated it Conti...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Orphazyme (NASDAQ: ORPH ) and ORPH stock are seeing impressive gains. Shares of this biopharma company are currently up more than 4% at the time of writing on a very green day in the over...
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...